Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 15 Best Boring Dividend Stocks to Buy. On November 24, Truist’s Gregory Renza initiated coverage of Gilead Sciences, Inc. (NASDAQ:GILD) ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best pharma stocks to invest in. Cantor Fitzgerald analyst Carter Gould ...
Evercore ISI analyst Umer Raffat maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday. The company’s shares closed yesterday at $103.31. Leverage the power of TipRanks' Smart ...
Deutsche Bank upgraded Gilead (GILD) to Buy from Hold with a price target of $120, up from $80. The company’s core HIV treatment franchise should drive steady revenue growth deep into to the 2030s, ...
How much is a fast track for the Food and Drug Administration review of a new drug worth? Try $125 million. In an auction, Gilead Sciences, a maker of HIV and hepatitis medicines, just bought a coupon ...
Gilead is down 16% from its recent high in a strong market. This seems warranted given the analyst estimates for the coming years. However, Gilead is investing heavily into R&D and made a promising ...
Since it’s a publicly traded company, anyone can buy Gilead Sciences stock. Here’s a step-by-step guide on how to invest money in the pharmaceutical stock: Step 1: Open your brokerage account: Log in ...
(Reuters) - Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class ...
On the last day of trading in 2016, Gilead Sciences' (NASDAQ: GILD) stock price closed at $71.61 per share. Fast-forward one year, and Gilead's share price at the end of 2017 was $71.64. Over the ...
There's no question that Gilead can afford to make more deals. The big biotech reported $36.7 billion in cash, cash equivalents, and marketable securities at the end of 2017. Gilead also has ample ...
Medical pioneer Gilead Sciences GILD has seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks. Gilead has joined Johnson & Johnson JNJ, and a cluster of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback